Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin type A therapy for blepharospasm.

J Costa1, C Espírito-Santo, A Borges

  • 1Instituto de Farmacologia e Terapêutica Geral, Faculdade de Medicina Lisboa, Av. Prof. Egas Moniz, Lisboa, Portugal, 1649-028. joaoncosta@sapo.pt

The Cochrane Database of Systematic Reviews
|January 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2024
Same author

Viewpoint: «Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use.

The journal of prevention of Alzheimer's disease·2023
Same author

Biofilm formation under high shear stress increases resilience to chemical and mechanical challenges.

Biofouling·2021
Same author

Use of fluoridated dentifrices by children in Araçatuba, Brazil: factors affecting brushing habits and amount applied on the brush.

European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry·2021
Same author

Release-Recapture Test of Dispersal and Survival of Sterile Males of Ceratitis capitata (Diptera: Tephritidae).

Neotropical entomology·2020
Same author

Improved patient outcomes using the enhanced recovery pathway in breast microsurgical reconstruction: a UK experience.

JPRAS open·2020

Botulinum toxin type A (BtA) shows high efficacy for blepharospasm, with about 90% of patients benefiting. However, high-quality randomized controlled trials are lacking, making further placebo-controlled studies unethical.

Area of Science:

  • Neurology
  • Ophthalmology
  • Pharmacology

Background:

  • Blepharospasm is a focal dystonia causing involuntary eyelid closure due to orbicularis oculi muscle contractions.
  • It is a chronic, often lifelong disorder with variable severity, potentially leading to functional blindness.
  • Botulinum toxin type A (BtA) is the primary therapeutic agent.

Purpose of the Study:

  • To evaluate the efficacy and safety of botulinum toxin (BtA) for treating blepharospasm.
  • To synthesize evidence from randomized controlled trials (RCTs).

Main Methods:

  • Comprehensive literature search across multiple databases (Cochrane, MEDLINE, EMBASE) and conference abstracts.
  • Inclusion criteria: randomized, placebo-controlled trials evaluating BtA efficacy for blepharospasm.

Related Experiment Videos

  • Data extraction and validity assessment by two independent reviewers; outcomes included adverse events, symptom improvement, and quality of life.

    • Main Results:

    • Few controlled trials were identified, characterized by short duration, small sample sizes, and poor internal validity.
    • Despite methodological limitations, all trials indicated BtA superiority over placebo.
    • Larger case-control and cohort studies reported approximately 90% patient benefit.

    Conclusions:

    • Currently, high-quality RCT data supporting BtA efficacy for blepharospasm is insufficient.
    • Existing evidence from open studies strongly suggests BtA is highly effective and safe.
    • Further placebo-controlled trials are deemed unethical due to the high observed benefit rate; future research should focus on optimizing treatment parameters and exploring long-term outcomes.